TwinBeech Capital’s Epizyme, Inc EPZM Stock Holding History

TwinBeech Capital’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-14,972	Closed	-$179K	–	675
2020 Q3	$179K	Buy	+14,972	New	+$201K	0.04%	391

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KXA

KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

TwinBeech Capital's EPZM Position: Q4 2020 in Review

TwinBeech Capital sold out of Epizyme, Inc (EPZM) in Q4 2020, closing a stake of 14,972 shares — an estimated $179K sold.

TwinBeech Capital first reported a position in EPZM in Q3 2020 and held it in 1 quarter. The position peaked at $179K in Q3 2020. 137 funds tracked by Wall St. Rank hold EPZM as of Q4 2020.

TwinBeech Capital reported no remaining Epizyme, Inc position as of Q4 2020 after selling out during the quarter.
TwinBeech Capital sold 14,972 Epizyme, Inc shares in Q4 2020, an estimated $179K.
TwinBeech Capital first reported a position in Epizyme, Inc in Q3 2020 and held it in 1 quarter.
TwinBeech Capital's Epizyme, Inc position peaked at $179K in Q3 2020.
137 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2020.

Based on TwinBeech Capital's 13F filing for Q4 2020, filed 16 Feb 2021.